{"id":"mirena-bay86-5028","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Irregular bleeding or spotting"},{"rate":"20","effect":"Amenorrhea"},{"rate":"5-10","effect":"Pelvic pain or cramping"},{"rate":"5","effect":"Headache"},{"rate":"3-5","effect":"Breast tenderness"},{"rate":"3-5","effect":"Acne"},{"rate":"2-5","effect":"Device expulsion"}]},"_chembl":{"chemblId":"CHEMBL586875","moleculeType":"Small molecule","molecularWeight":"384.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mirena is a T-shaped intrauterine device (IUD) that continuously releases the synthetic progestin levonorgestrel into the uterine cavity. This local hormonal delivery thickens cervical mucus, inhibits sperm transport, and suppresses endometrial proliferation, resulting in contraceptive efficacy and reduced menstrual flow. The device provides long-acting reversible contraception for up to 5 years.","oneSentence":"Mirena releases levonorgestrel directly into the uterus to prevent pregnancy and reduce menstrual bleeding through local hormonal suppression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:35.186Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception"},{"name":"Heavy menstrual bleeding (menorrhagia)"}]},"trialDetails":[{"nctId":"NCT06904274","phase":"PHASE3","title":"Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-11-24","conditions":"Endometrial Hyperplasia","enrollment":207},{"nctId":"NCT03074045","phase":"PHASE3","title":"LCS16 vs. COC User Satisfaction and Tolerability Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-03-13","conditions":"Contraception","enrollment":145},{"nctId":"NCT02349815","phase":"","title":"JAYDESS Drug Utilization Study in Sweden","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-01-01","conditions":"Contraception","enrollment":10000},{"nctId":"NCT02985541","phase":"PHASE3","title":"Mirena Extension Trial","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-12-22","conditions":"Contraception","enrollment":364},{"nctId":"NCT02475356","phase":"","title":"Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-04","conditions":"Menorrhagia, Dysmenorrhea","enrollment":601},{"nctId":"NCT03754556","phase":"","title":"Study on Medical Records of Women Using an Intrauterine Device (IUD) to Analyze the Risks That the IUD Will be Expelled or Perforates the Womb in Relation to Breastfeeding, the Point in Time When the IUD Was Inserted After Childbirth and in Relation to Different Types of IUDs","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-03","conditions":"Intrauterine Devices","enrollment":326658},{"nctId":"NCT03562624","phase":"PHASE2","title":"A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-22","conditions":"Contraception","enrollment":177},{"nctId":"NCT02903888","phase":"","title":"A Cross-sectional, Observational Multicenter Study to Assess the Reasons for Choosing the 3-year Hormonal IUD and Level of IUDs Knowledge Among Women Aged 18 to 29 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-08","conditions":"Intrauterine Devices, Medicated","enrollment":886},{"nctId":"NCT01254292","phase":"PHASE3","title":"LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-06","conditions":"Contraception","enrollment":567},{"nctId":"NCT02414919","phase":"","title":"Duration of Use of Highly Effective Reversible Contraception","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-04-01","conditions":"Pregnancy","enrollment":13880},{"nctId":"NCT00883662","phase":"","title":"Mirena Observational Program","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-05","conditions":"Contraception, Menorrhagia, Endometrial Hyperplasia","enrollment":2725},{"nctId":"NCT01590537","phase":"","title":"Non-interventional Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-09","conditions":"Contraception","enrollment":2348},{"nctId":"NCT01958684","phase":"","title":"Bleeding Pattern Difference Between Levonorgestrel Intrauterine System (LNG-IUS) and Copper Intrauterine Devices (IUDs) Immediately Inserted After Abortion","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10","conditions":"Contraception","enrollment":512},{"nctId":"NCT01833793","phase":"","title":"Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02","conditions":"Female Contraception","enrollment":35},{"nctId":"NCT01434160","phase":"PHASE3","title":"LCS12 Adolescent Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-09","conditions":"Contraception","enrollment":304},{"nctId":"NCT00864136","phase":"","title":"Mirena or Conventional Medical Treatment for Menorrhagia","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-11","conditions":"Menorrhagia","enrollment":647},{"nctId":"NCT00185380","phase":"PHASE2","title":"Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-04","conditions":"Contraception","enrollment":742},{"nctId":"NCT00798980","phase":"","title":"Scandinavian Mirena Insertion Nulliparous Trial.","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-02","conditions":"Nulliparous","enrollment":224},{"nctId":"NCT00868153","phase":"","title":"Mirena in Idiopathic Menorrhagia","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-08","conditions":"Idiopathic Menorrhagia","enrollment":1125},{"nctId":"NCT00696202","phase":"PHASE4","title":"Mirena Efficiency and Tolerability During the First Year of Use","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-09","conditions":"Medicated Intrauterine Devices, Contraception","enrollment":199},{"nctId":"NCT01295294","phase":"PHASE4","title":"Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-03","conditions":"Uterine Hemorrhage","enrollment":187},{"nctId":"NCT00393198","phase":"PHASE4","title":"Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-10","conditions":"Contraception, Menorrhagia","enrollment":204},{"nctId":"NCT00874653","phase":"","title":"Survey on Patient Satisfaction Rate for Mirena Use in Heavy Menstrual Bleeding","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Menorrhagia","enrollment":78},{"nctId":"NCT01414140","phase":"","title":"Mirena Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":"Contraception","enrollment":567},{"nctId":"NCT00931827","phase":"","title":"Acceptability of Long-term Progestin-only Contraception in Europe","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-01","conditions":"Contraception","enrollment":436},{"nctId":"NCT00360490","phase":"PHASE3","title":"Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-07","conditions":"Menorrhagia","enrollment":165},{"nctId":"NCT01085487","phase":"","title":"MiCo - Mirena or Conventional Medical Treatment for Menorrhagia","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-04","conditions":"Idiopathic Menorrhagia","enrollment":1211}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mirena (BAY86-5028)","genericName":"Mirena (BAY86-5028)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mirena releases levonorgestrel directly into the uterus to prevent pregnancy and reduce menstrual bleeding through local hormonal suppression. Used for Contraception, Heavy menstrual bleeding (menorrhagia).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}